WILSON LARRY Y

Form 4

September 13, 2007

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287 January 31,

0.5

Check this box if no longer

subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Expires: 2005 Estimated average

OMB APPROVAL

burden hours per response...

Form 5 obligations may continue.

See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person *

(First)

(Street)

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to

Issuer

WILSON LARRY Y

Symbol

CHOLESTECH CORPORATION

[CTEC]

(Check all applicable)

(Middle)

3. Date of Earliest Transaction (Month/Day/Year)

X_ Director 10% Owner Officer (give title Other (specify below)

3347 INVESTMENT BLVD.

09/12/2007

6. Individual or Joint/Group Filing(Check

4. If Amendment, Date Original Filed(Month/Day/Year)

Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

HAYWARD, CA 94545

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) Execution Date, if (Instr. 3) (Month/Day/Year)

4. Securities 3. TransactionAcquired (A) or Code Disposed of (D) (Instr. 3, 4 and 5) (Instr. 8)

5. Amount of Securities Beneficially Owned Following

6. Ownership 7. Nature of Form: Direct Indirect Beneficial (D) or Indirect (I) Ownership (Instr. 4) (Instr. 4)

(A) or

Reported Transaction(s)

(Instr. 3 and 4) Code V Amount (D) Price

D

Common Stock

09/12/2007

09/12/2007

D 4,000 (1) 0 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: WILSON LARRY Y - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Right to Buy (Employee Stock Option)	\$ 12.5	09/12/2007	09/12/2007	D	15,000	<u>(2)</u>	08/14/2012	Common Stock	15,000
Right to Buy (Employee Stock Option)	\$ 9.15	09/12/2007	09/12/2007	D	15,000	(3)	08/14/2010	Common Stock	15,000
Right to Buy (Employee Stock Option)	\$ 7.32	09/12/2007	09/12/2007	D	15,000	<u>(4)</u>	08/18/2011	Common Stock	15,000
Right to Buy (Employee Stock Option)	\$ 10.75	09/12/2007	09/12/2007	D	15,000	<u>(5)</u>	08/17/2012	Common Stock	15,000
Right to Buy (Employee Stock Option)	\$ 10.94	09/12/2007	09/12/2007	D	15,000	<u>(6)</u>	08/16/2013	Common Stock	15,000

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
WILSON LARRY Y	***					
3347 INVESTMENT BLVD.	X					
HAYWARD, CA 94545						

Reporting Owners 2

Edgar Filing: WILSON LARRY Y - Form 4

Date

Signatures

John F. Glenn, Atty-in-Fact for Larry Y.
Wilson

09/13/2007

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Disposed of pursuant to a merger agreement between the issuer, Inverness Medical Innovations, Inc. ("IMA") and Iris Merger Sub, Inc. in exchange for 1,745 shares of IMA Common Stock having a market value of \$48.56 per share on the effective date of the merger, and \$33.02 representing fractional shares as provided in the merger agreement.
- (2) This option provided for vesting over 4 years. Upon effectiveness of the merger, this option was exchanged for an option to purchase 6,546 shares of IMA Common Stock with an exercise price of \$28.65 per share.
- (3) This option provided for vesting over 4 years. Upon effectiveness of the merger, this option was exchanged for an option to purchase 6,546 shares of IMA Common Stock with an exercise price of \$20.97 per share.
- (4) This option provided for vesting over 4 years. Upon effectiveness of the merger, this option was exchanged for an option to purchase 6,546 shares of IMA Common Stock with an exercise price of \$16.78 per share.
- (5) This option provided for vesting over 4 years. Upon effectiveness of the merger, this option was exchanged for an option to purchase 6,546 shares of IMA Common Stock with an exercise price of \$24.64 per share.
- (6) This option provided for vesting over 4 years. Upon effectiveness of the merger, this option was exchanged for an option to purchase 6,546 shares of IMA Common Stock with an exercise price of \$25.07 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3